The authors also concluded that, for the purposes of future anti-obesity drug development programs, targeting only the NPY Y5 receptor was unlikely to produce therapeutic efficacy [42]. This evidence concerns the gene NPY5R and obesity due to melanocortin 4 receptor deficiency.